Phreesia Q4 Earnings Report Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy PHR?
Source: seekingalpha
- Earnings Miss: Phreesia reported a Q4 GAAP EPS of $0.02, falling short of expectations by $0.04, indicating potential challenges in profitability that may affect investor confidence.
- Significant Revenue Growth: The company achieved revenue of $127.07 million, representing a 15.9% year-over-year increase and exceeding expectations by $0.44 million, suggesting strong market demand that could lay the groundwork for future growth.
- Market Reaction Analysis: Despite the revenue beat, the earnings miss may pressure the stock price in the short term, prompting investors to monitor the company's strategies for improving profitability.
- Future Outlook: With ongoing revenue growth, Phreesia may need to optimize its cost structure to enhance profitability, thereby strengthening its competitive position and attracting more investor interest.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHR
Wall Street analysts forecast PHR stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.400
Low
24.00
Averages
29.09
High
35.00
Current: 8.400
Low
24.00
Averages
29.09
High
35.00
About PHR
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Surge on Hopes for End to Iran War
- Market Rally: The S&P 500 index rose by 2.91%, the Dow Jones Industrial Average by 2.49%, and the Nasdaq 100 by 3.43%, reflecting market optimism regarding the potential end of the Iran war, which could lower energy prices and ease inflation concerns.
- Consumer Confidence Boost: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing the anticipated decline to 87.9, indicating a strengthening consumer outlook that may drive spending and economic growth.
- Strength in China: China's March manufacturing PMI rose to 50.4, better than the expected 50.1, signaling signs of economic recovery that could positively impact global growth prospects and further support US stock performance.
- Falling Bond Yields: The 10-year Treasury note yield dropped to 4.28%, a one-week low, reflecting reduced inflation worries, which may provide support for the stock market and enhance investor interest in equities.
See More
Phreesia Inc Shares Enter Oversold Territory
- Oversold Signal: Phreesia Inc (Ticker: PHR) saw its RSI drop to 26.0 during Tuesday's trading, indicating that its stock price, which hit a low of $7.77, has entered oversold territory, suggesting that recent heavy selling may be nearing exhaustion and providing potential buying opportunities for investors.
- Market Comparison: Compared to the current RSI of 43.5 for the S&P 500 ETF (SPY), PHR's oversold condition may attract bullish investors, particularly in a market where overall performance remains relatively strong, potentially leading to increased capital inflow.
- Price Volatility: With a 52-week low of $7.77 and a high of $32.76, PHR's current trading price of $8.38 indicates significant price fluctuations, suggesting potential for a rebound that may catch the attention of short-term traders.
- Investor Sentiment: Despite the current low stock price, investor sentiment towards PHR may turn optimistic due to the oversold signal, especially as interest in other oversold stocks rises, which could drive its stock price higher.
See More
US Stocks Surge as Market Sentiment Improves
- Market Sentiment Improves: The S&P 500 index rose by 1.02%, the Dow Jones Industrial Average increased by 0.67%, and the Nasdaq 100 surged by 1.10% as President Trump signaled a willingness to end military actions against Iran, reflecting investor optimism over easing geopolitical risks.
- Falling Bond Yields: The 10-year Treasury note yield dropped to a one-week low of 4.30%, indicating market expectations that an end to the Iran conflict could lower energy prices and alleviate inflation concerns, further supporting stock market gains.
- Consumer Confidence Rises: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing expectations of a decline to 87.9, suggesting enhanced consumer confidence in economic prospects, which could drive spending and economic growth.
- Strong Chinese Economy: China's March manufacturing PMI rose to 50.4, exceeding expectations of 50.1, indicating signs of economic recovery that support global growth prospects and positively influence market performance.
See More
Phreesia Stock Plummets After Mixed Q4 Earnings Report
- Earnings Report Disappointment: Phreesia's Q4 2026 earnings report revealed a revenue of $127.1 million, surpassing expectations, yet the earnings per share of $0.02 fell significantly short of the anticipated $0.06, resulting in a 27.5% stock drop in early trading.
- Sales Growth Highlight: Despite the earnings miss, Phreesia achieved a 16% year-over-year sales increase and reported profitability for both the quarter and the full year at $0.04 per share, indicating some resilience in the market.
- Free Cash Flow Performance: The company generated a positive free cash flow of $28.5 million for the quarter and $54.4 million for the year, reflecting a solid cash position after accounting for capital expenditures and software costs, despite the earnings challenges.
- Cautious Future Outlook: Phreesia lowered its fiscal 2027 revenue guidance to $510 million to $520 million from a previous range of $545 million to $559 million, highlighting uncertainty regarding spending commitments from pharmaceutical clients, although it still anticipates a 7% growth.
See More
US Stocks Surge as Market Sentiment Improves
- Market Rebound: The S&P 500 Index rose by 1.33%, the Dow Jones Industrial Average increased by 1.10%, and the Nasdaq 100 Index climbed by 1.45%, reflecting investor optimism following President Trump's willingness to end military actions against Iran, potentially easing geopolitical tensions.
- Supportive Economic Data: China's March manufacturing PMI rose by 1.4 to 50.4, surpassing expectations of 50.1, indicating signs of economic recovery that could enhance global growth prospects and drive stock markets higher.
- Falling Bond Yields: The 10-year T-note yield dropped to 4.30%, a one-week low, as WTI crude oil prices fell, alleviating inflation concerns and lowering borrowing costs, thereby supporting further gains in the stock market.
- Tech Stocks Lead Gains: The
See More
PEPG, SGMO, and PHR Shares Decline Amid Disappointing Results
- PEPG Trial Disappointment: PepGen's Phase 2 Freedom 2 study results showed no significant improvements in walking speed or hand strength at the starting dose of 5 mg/kg, leading to a 45% plunge in premarket trading, reflecting investor disappointment in the therapy's efficacy.
- SGMO Earnings Miss: Sangamo Therapeutics reported a Q4 loss per share of $0.11, wider than the expected $0.05 loss, despite revenue rising to $14.23 million, indicating pressure on the company's funding outlook that may impact future operations.
- PHR Revenue Outlook Cut: Phreesia lowered its fiscal 2027 revenue outlook to $510 million to $520 million, below analyst expectations of $552.1 million, resulting in a 27% drop in share price and prompting downgrades from multiple brokerages.
- Market Sentiment Fluctuates: While retail sentiment for PEPG, SGMO, and PHR on Stocktwits was 'extremely bullish', the disappointing performance and unclear outlook have severely undermined investor confidence, reflecting a cautious attitude towards biotech stocks.
See More
US Stocks Surge on Hopes for End to Iran War
- Market Rally: The S&P 500 index rose by 2.91%, the Dow Jones Industrial Average by 2.49%, and the Nasdaq 100 by 3.43%, reflecting market optimism regarding the potential end of the Iran war, which could lower energy prices and ease inflation concerns.
- Consumer Confidence Boost: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing the anticipated decline to 87.9, indicating a strengthening consumer outlook that may drive spending and economic growth.
- Strength in China: China's March manufacturing PMI rose to 50.4, better than the expected 50.1, signaling signs of economic recovery that could positively impact global growth prospects and further support US stock performance.
- Falling Bond Yields: The 10-year Treasury note yield dropped to 4.28%, a one-week low, reflecting reduced inflation worries, which may provide support for the stock market and enhance investor interest in equities.
See More
Phreesia Inc Shares Enter Oversold Territory
- Oversold Signal: Phreesia Inc (Ticker: PHR) saw its RSI drop to 26.0 during Tuesday's trading, indicating that its stock price, which hit a low of $7.77, has entered oversold territory, suggesting that recent heavy selling may be nearing exhaustion and providing potential buying opportunities for investors.
- Market Comparison: Compared to the current RSI of 43.5 for the S&P 500 ETF (SPY), PHR's oversold condition may attract bullish investors, particularly in a market where overall performance remains relatively strong, potentially leading to increased capital inflow.
- Price Volatility: With a 52-week low of $7.77 and a high of $32.76, PHR's current trading price of $8.38 indicates significant price fluctuations, suggesting potential for a rebound that may catch the attention of short-term traders.
- Investor Sentiment: Despite the current low stock price, investor sentiment towards PHR may turn optimistic due to the oversold signal, especially as interest in other oversold stocks rises, which could drive its stock price higher.
See More
US Stocks Surge as Market Sentiment Improves
- Market Sentiment Improves: The S&P 500 index rose by 1.02%, the Dow Jones Industrial Average increased by 0.67%, and the Nasdaq 100 surged by 1.10% as President Trump signaled a willingness to end military actions against Iran, reflecting investor optimism over easing geopolitical risks.
- Falling Bond Yields: The 10-year Treasury note yield dropped to a one-week low of 4.30%, indicating market expectations that an end to the Iran conflict could lower energy prices and alleviate inflation concerns, further supporting stock market gains.
- Consumer Confidence Rises: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing expectations of a decline to 87.9, suggesting enhanced consumer confidence in economic prospects, which could drive spending and economic growth.
- Strong Chinese Economy: China's March manufacturing PMI rose to 50.4, exceeding expectations of 50.1, indicating signs of economic recovery that support global growth prospects and positively influence market performance.
See More
Phreesia Stock Plummets After Mixed Q4 Earnings Report
- Earnings Report Disappointment: Phreesia's Q4 2026 earnings report revealed a revenue of $127.1 million, surpassing expectations, yet the earnings per share of $0.02 fell significantly short of the anticipated $0.06, resulting in a 27.5% stock drop in early trading.
- Sales Growth Highlight: Despite the earnings miss, Phreesia achieved a 16% year-over-year sales increase and reported profitability for both the quarter and the full year at $0.04 per share, indicating some resilience in the market.
- Free Cash Flow Performance: The company generated a positive free cash flow of $28.5 million for the quarter and $54.4 million for the year, reflecting a solid cash position after accounting for capital expenditures and software costs, despite the earnings challenges.
- Cautious Future Outlook: Phreesia lowered its fiscal 2027 revenue guidance to $510 million to $520 million from a previous range of $545 million to $559 million, highlighting uncertainty regarding spending commitments from pharmaceutical clients, although it still anticipates a 7% growth.
See More
US Stocks Surge as Market Sentiment Improves
- Market Rebound: The S&P 500 Index rose by 1.33%, the Dow Jones Industrial Average increased by 1.10%, and the Nasdaq 100 Index climbed by 1.45%, reflecting investor optimism following President Trump's willingness to end military actions against Iran, potentially easing geopolitical tensions.
- Supportive Economic Data: China's March manufacturing PMI rose by 1.4 to 50.4, surpassing expectations of 50.1, indicating signs of economic recovery that could enhance global growth prospects and drive stock markets higher.
- Falling Bond Yields: The 10-year T-note yield dropped to 4.30%, a one-week low, as WTI crude oil prices fell, alleviating inflation concerns and lowering borrowing costs, thereby supporting further gains in the stock market.
- Tech Stocks Lead Gains: The
See More
PEPG, SGMO, and PHR Shares Decline Amid Disappointing Results
- PEPG Trial Disappointment: PepGen's Phase 2 Freedom 2 study results showed no significant improvements in walking speed or hand strength at the starting dose of 5 mg/kg, leading to a 45% plunge in premarket trading, reflecting investor disappointment in the therapy's efficacy.
- SGMO Earnings Miss: Sangamo Therapeutics reported a Q4 loss per share of $0.11, wider than the expected $0.05 loss, despite revenue rising to $14.23 million, indicating pressure on the company's funding outlook that may impact future operations.
- PHR Revenue Outlook Cut: Phreesia lowered its fiscal 2027 revenue outlook to $510 million to $520 million, below analyst expectations of $552.1 million, resulting in a 27% drop in share price and prompting downgrades from multiple brokerages.
- Market Sentiment Fluctuates: While retail sentiment for PEPG, SGMO, and PHR on Stocktwits was 'extremely bullish', the disappointing performance and unclear outlook have severely undermined investor confidence, reflecting a cautious attitude towards biotech stocks.
See More
